FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.